Literature DB >> 24819501

Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST).

Yezi Zhu1, Chengfei Liu, Yuanyuan Cui, Nagalakshmi Nadiminty, Wei Lou, Allen C Gao.   

Abstract

BACKGROUND: Paracrine interleukin-6 (IL-6) can mediate neuroendocrine (NE) features, including the acquisition of a neurite-like phenotype and growth arrest in prostate cancer cells. However, little is known about the mechanisms underlying neuroendocrine differentiation induced by IL-6.
METHODS: Immunoblotting was performed to determine the status of RE1-silencing transcription factor (REST) and of neuroendocrine markers such as Neuron-specific Enolase (NSE), chromogranin A and synaptophysin in LNCaP cells treated with IL-6. To further study the impact of REST-mediated repression on neuroendocrine differentiation (NED) in LNCaP cells, either wild-type REST or a dominant-positive form of REST, REST-VP16, in which both repressor domains of REST were replaced with the activation domain of the herpes simplex virus protein VP16, was introduced into LNCaP cells.
RESULTS: In this study, we show that REST is suppressed in IL-6-induced neuroendocrine differentiation in LNCaP cells. Overexpression of exogenous REST abrogated IL-6-induced NED in prostate cancer cells. Expression of the recombinant REST-VP16 fusion protein activated REST target genes and other neuronal differentiation genes and produced neuronal physiological properties. In addition, REST protein turnover was accelerated in IL-6 induced NE differentiated LNCaP cells via the ubiquitin-proteasome pathway, accompanied by a decrease in the expression of the deubiquitylase HAUSP, indicating that pathway(s) priming REST degradation may be involved in IL-6 induced NE differentiation.
CONCLUSIONS: These results demonstrate that REST functions as a major switch of IL-6 induced neuroendocrine differentiation in LNCaP cells.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  REST; interleukin-6; neuroendocrine; prostate cancer

Mesh:

Substances:

Year:  2014        PMID: 24819501     DOI: 10.1002/pros.22819

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  37 in total

1.  Neuroendocrine prostate carcinoma cells originate from the p63-expressing basal cells but not the pre-existing adenocarcinoma cells in mice.

Authors:  Dong-Kee Lee; Yonghong Liu; Lan Liao; Wenliang Li; David Danielpour; Jianming Xu
Journal:  Cell Res       Date:  2019-02-18       Impact factor: 25.617

Review 2.  Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.

Authors:  Loredana Puca; Panagiotis J Vlachostergios; Himisha Beltran
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

3.  Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.

Authors:  Chengfei Liu; Wei Lou; Cameron Armstrong; Yezi Zhu; Christopher P Evans; Allen C Gao
Journal:  Prostate       Date:  2015-05-13       Impact factor: 4.104

4.  Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.

Authors:  Yezi Zhu; Chengfei Liu; Cameron Armstrong; Wei Lou; Amandeep Sandher; Allen C Gao
Journal:  Clin Cancer Res       Date:  2015-05-20       Impact factor: 12.531

5.  SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.

Authors:  Xiaotun Zhang; Ilsa M Coleman; Lisha G Brown; Lawrence D True; Lori Kollath; Jared M Lucas; Hung-Ming Lam; Ruth Dumpit; Eva Corey; Lisly Chéry; Bryce Lakely; Celestia S Higano; Bruce Montgomery; Martine Roudier; Paul H Lange; Peter S Nelson; Robert L Vessella; Colm Morrissey
Journal:  Clin Cancer Res       Date:  2015-06-12       Impact factor: 12.531

Review 6.  EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.

Authors:  Rama Soundararajan; Anurag N Paranjape; Sankar Maity; Ana Aparicio; Sendurai A Mani
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-07-05       Impact factor: 10.680

7.  REST Final-Exon-Truncating Mutations Cause Hereditary Gingival Fibromatosis.

Authors:  Yavuz Bayram; Janson J White; Nursel Elcioglu; Megan T Cho; Neda Zadeh; Asuman Gedikbasi; Sukru Palanduz; Sukru Ozturk; Kivanc Cefle; Ozgur Kasapcopur; Zeynep Coban Akdemir; Davut Pehlivan; Amber Begtrup; Claudia M B Carvalho; Ingrid Sophie Paine; Ali Mentes; Kivanc Bektas-Kayhan; Ender Karaca; Shalini N Jhangiani; Donna M Muzny; Richard A Gibbs; James R Lupski
Journal:  Am J Hum Genet       Date:  2017-07-06       Impact factor: 11.025

8.  MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness.

Authors:  Jingjing Li; Tianjie Pu; Lijuan Yin; Qinlong Li; Chun-Peng Liao; Boyang Jason Wu
Journal:  Oncogene       Date:  2020-02-17       Impact factor: 9.867

9.  Interleukin-6 Function and Targeting in Prostate Cancer.

Authors:  Zoran Culig
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  IL-4 Counteracts the Cytotoxic Effects of Peripheral Blood Mononuclear Cells on Hormone-sensitive Prostate Cancer Cells.

Authors:  Holger H H Erb; Zoran Culig; Matthias B Stope
Journal:  In Vivo       Date:  2021 Jul-Aug       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.